Table 4.
Patient characteristics associated with most common biopsy findings
| Characteristic | FSGS (n=35) | Immune-Complex GN (n=31) | Diabetic Nephropathy (n=14) | P Value |
|---|---|---|---|---|
| No. of APOL1 risk alleles | <0.001 | |||
| 0 allele | 3 (8) | 10 (32) | 7 (50) | |
| 1 allele | 10 (29) | 20 (64) | 4 (29) | |
| 2 alleles | 22 (63) | 1 (3) | 3 (21) | |
| Mean age, yr (SD) | 47.3 (7.2) | 45.5 (9.4) | 46.8 (9.1) | 0.45 |
| Women | 9 (26) | 12 (39) | 6 (43) | 0.39 |
| Diabetes | 2 (6) | 2 (6) | 14 (100) | <0.001 |
| Hypertension | 26 (74) | 16 (52) | 11 (78) | 0.08 |
| Hepatitis C | 16 (46) | 20 (64) | 7 (50) | 0.30 |
| Hepatitis B | 1 (3) | 2 (6) | 1 (7) | 0.74 |
| Illicit drug use history | 17 (49) | 19 (63) | 2 (15) | 0.01 |
| ACEi/ARB use at biopsy | 8 (23) | 7 (24) | 6 (43) | 0.33 |
| ACEi/ARB use after biopsy | 20 (64) | 12 (44) | 8 (67) | 0.23 |
| Mean HIV viral load, 1000 copies/ml (SD) | 68 (151) | 149 (217) | 26 (44) | 0.02 |
| HIV viral load <50 copies/ml at biopsy | 14 (40) | 7 (23) | 2 (18) | 0.22 |
| HIV viral suppression after biopsy | [n=32] | [n=28] | [n=11] | 0.61 |
| undetectable >90% of time | 16 (50) | 10 (36) | 3 (27) | |
| intermittent suppression | 6 (19) | 5 (18) | 3 (27) | |
| Mean CD4+cell count, cells/mm3 (SD) | 312 (239) | 299 (224) | 402 (362) | 0.66 |
| Mean prebiopsy nadir CD4+cell count, cells/mm3 (SD) | 179 (190) [n=30] | 180 (133) [n=29] | 269 (442) [n=11] | 0.77 |
| Mean proteinuria, mg/24 h or mg/g creatinine (SD) | 1920 (1686) | 2284 (2648) | 5173 (3663) | 0.005 |
| Mean serum creatinine, mg/dl (SD) | 2.5 (1.3) | 2.9 (2.5) | 2.6 (1.4) | 0.99 |
| Mean eGFR (CKD-EPI), ml/min per 1.73 m2 (SD) | 41.5 (22.1) | 49.9 (43.2) | 42.8 (28.5) | 0.93 |
Data are n (%) unless otherwise specified. ACEi, ACE-inhibitor; ARB, angiotensin receptor blocker; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated GFR.